

PHARMACY POLICY STATEMENT

Common Ground Healthcare Cooperative (CGHC)

| | |
|-------------------------|---|
| DRUG NAME | Bethkis (tobramycin inhalation solution) |
| BILLING CODE | Must use valid NDC |
| BENEFIT TYPE | Pharmacy |
| SITE OF SERVICE ALLOWED | Home |
| STATUS | Prior Authorization Required |

Bethkis (tobramycin inhalation solution) is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with *Pseudomonas aeruginosa* initially approved by the FDA in 2012. Cystic fibrosis is an autosomal recessive disease in which patients can have abnormal airways secretions, chronic endobronchial infection, and progressive airway obstruction.

Bethkis (tobramycin inhalation solution) will be considered for coverage when the following criteria are met:

Cystic Fibrosis

For **initial** authorization:

1. Member is at least 6 years of age; AND
2. Medication is prescribed by a pulmonologist or an infectious disease specialist; AND
3. Member has a diagnosis of cystic fibrosis with a positive culture for *Pseudomonas aeruginosa* documented in chart notes; AND
4. Member has documented forced expiratory volume in 1 second (FEV₁) of 40% to 80% predicted; AND
5. Member is not colonized with *Burkholderia cepacia*; AND
6. Member has tried and failed generic tobramycin inhalation solution and ineffectiveness, intolerance or contraindication is documented in chart notes.
7. **Dosage allowed/Quantity limit:** 300 mg twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug (224 mL per 56 days).

If all the above requirements are met, the medication will be approved for 12 months.

For **reauthorization**:

1. Chart notes must show improvement or stabilized signs and symptoms of disease defined as any of the following:
 - a) Improved FEV1 and/or other lung function tests
 - b) Decrease in pulmonary exacerbations or hospitalization
 - c) Decrease in pulmonary infections

If all the above requirements are met, the medication will be approved for an additional 12 months.



HEALTHCARE COOPERATIVE

CareSource considers Bethkis (tobramycin inhalation solution) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

| DATE | ACTION/DESCRIPTION |
|------------|--|
| 06/12/2017 | New policy for Bethkis created. Not covered diagnosis added. |
| 12/29/2020 | Quantity limit changed to 56 days from 28 days. Reauthorization criteria updated to ask for evidence of disease stability or improvement. Diagnosis of cystic fibrosis added to initial criteria. Kitabis removed as preferred option. Exclusion criteria updated to a simplified statement. |
| 4/26/2022 | Policy transferred to new template. Added references. Amended renewal criteria to reflect expected treatment response; removed sweat chloride and weight gain. |

References:

1. Bethkis [package insert]. Woodstock, IL: Cornerstone Therapeutics, Inc.; 2012.
2. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. *Am J Respir Crit Care Med.* 2013;187(7):680-689. doi:10.1164/rccm.201207-1160oe
3. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial *Pseudomonas aeruginosa* infection. *Ann Am Thorac Soc.* 2014;11(10):1640-1650. doi:10.1513/AnnalsATS.201404-166OC
4. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis [published online ahead of print, 2018 Mar 30]. *Cochrane Database Syst Rev.* 2018;3(3):CD001021. doi:10.1002/14651858.CD001021.pub3

Effective date: 01/01/2025

Revised date: 04/26/2022